866-997-4948(US-Canada Toll Free)

Anal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Published By :

GlobalData

Published Date : Feb 2012

Category :

Cancer

No. of Pages : 66 Pages


GlobalData, the industry analysis specialist, has released its new report, Anal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Anal Cancer Therapeutics market. The report identifies the key trends shaping and driving the global Anal Cancer Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Anal Cancer Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Anal Cancer Therapeutics market. Its scope includes -
  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Anal Cancer Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. 
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Anal Cancer Therapeutics market. 
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Anal Cancer Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Anal Cancer Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 
  • Develop business strategies by understanding the trends shaping and driving the global Anal Cancer Therapeutics market. 
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Anal Cancer Therapeutics market in future. 
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 
  • Whats the next big thing in the global Anal Cancer Therapeutics market landscape? Identify, understand and capitalize.
Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5

2 Anal Cancer Therapeutics - Introduction 6
2.1 Overview 6
2.2 Epidemiology 6
2.3 Etiology and Pathophysiology 7
2.4 Risk Factors for Anal Cancer 8
2.5 Symptoms 8
2.6 Diagnosis 9
2.6.1 Physical Exam and History 9
2.6.2 Endoscopy 10
2.6.3 Biopsy 10
2.6.4 Ultrasound 10
2.6.5 Digital Rectal Examination (DRE) 10
2.6.6 CT (Computerized Tomography) Scan 10
2.6.7 Human Papillomavirus Test 10
2.6.8 Other Recent Methods to Detect HPV Infections 10
2.7 Staging of Anal Cancer 11
2.8 Treatment for Patients with Anal Cancer 14
2.8.1 Surgery 14
2.8.2 Radiation Therapy 14
2.8.3 Chemotherapy 15
2.8.4 Limitations of Current HPV Vaccines 17
2.9 Treatment by Stage of the Disease 18
2.10 GlobalData Pipeline Report Guidance 19

3 Anal Cancer Therapeutics - Market Characterization 20
3.1 Anal Cancer Therapeutics Market Size (2006-2011) - Global 20
3.2 Anal Cancer Therapeutics Market Forecast (2011-2019) - Global 22
3.3 Anal Cancer Therapeutics Market Size (2006-2011) - The US 24
3.4 Anal Cancer Therapeutics Market Forecast (2011-2019) - The US 25
3.5 Anal Cancer Therapeutics Market Size (2006-2011) - The UK 26
3.6 Anal Cancer Therapeutics Market Forecast (2011-2019) - The UK 27
3.7 Anal Cancer Therapeutics Market Size (2006-2011) - France 28
3.8 Anal Cancer Therapeutics Market Forecast (2011-2019) - France 29
3.9 Anal Cancer Therapeutics Market Size (2006-2011) - Germany 30
3.10 Anal Cancer Therapeutics Market Forecast (2011-2019) - Germany 31
3.11 Anal Cancer Therapeutics Market Size (2006-2011) - Italy 32
3.12 Anal Cancer Therapeutics Market Forecast (2011-2019) - Italy 33
3.13 Anal Cancer Therapeutics Market Size (2006-2011) - Spain 34
3.14 Anal Cancer Therapeutics Market Forecast (2011-2019) - Spain 35
3.15 Anal Cancer Therapeutics Market Size (2006-2011) - Japan 36
3.16 Anal Cancer Therapeutics Market Forecast (2011-2019) - Japan 37
3.17 Drivers and Barriers for the Anal Cancer Therapeutics Market 38
3.17.1 Drivers for the Anal Cancer Therapeutics Market 38
3.17.2 Barriers for the Anal Cancer Therapeutics Market 38
3.18 Opportunity and Unmet Need 40
3.18.1 Opportunity and Unmet Need for the Anal Cancer Therapeutics Market 40
3.19 Key Takeaway 41

4 Anal Cancer Therapeutics Market - Competitive Assessment 42
4.1 Overview 42
4.2 Strategic Competitor Assessment 42
4.2.1 Competitor Assessment within Different Categories Employed in Anal Cancer Treatment 42
4.3 Product Profile for Recommended Regimens for Anal Cancer Therapeutics Market 43
4.3.1 5- Fluorouracil in Combination with Mitomycin 43
4.3.2 5- FU in Combination with Cisplatin 44
4.3.3 Prophylactic Vaccine Used for Anal Cancer: Gardasil 44
4.4 Key Takeaway 45

5 Anal Cancer Therapeutics - Pipeline Assessment 46
5.1 Overview 46
5.2 Strategic Pipeline Assessment 46
5.3 Anal Cancer Therapeutics - Pipeline by Phases of Development 46
5.3.1 Anal Cancer Therapeutics - Phase II Pipeline 47
5.3.2 Anal Cancer Therapeutics - Phase I Pipeline 47
5.3.3 Anal Cancer Therapeutics - Preclinical Pipeline 48
5.4 Anal Cancer Therapeutics- Pipeline by Mechanism of Action 49
5.4.1 Technology Trends Analytic Framework 50
5.5 Molecule Profile for Drugs under Clinical Development 50
5.5.1 Panitumumab in Combination with mitomicin C, 5-FU and Radiation Therapy 50
5.5.2 TheraCIM (Nimotuzumab) in Combination with Radiation Therapy 51
5.6 Key Takeaway 51

6 Anal Cancer Therapeutics - Clinical Trials Mapping 52
6.1 Clinical Trials by Country (US, EU5 and Japan) 52
6.2 Clinical Trials by Phase 53
6.3 Clinical Trials by Status 54
6.4 Overall Sponsors 55
6.5 Prominent Sponsors 56

7 Anal Cancer Therapeutics - Strategic Assessment 57
7.1 Anal Cancer Therapeutics - Implications for Future Market Competition 57

8 Anal Cancer Therapeutics - Future Players 58
8.1 Introduction 58
8.2 Company Profiles 59
8.2.1 YM BioSciences Inc. (YM BioSciences) 59
8.2.2 PDS Biotechnology Corporation (PDS) 59

9 Anal Cancer Therapeutics - Appendix 60
9.1 Market Definitions 60
9.2 Abbreviations 60
9.3 Methodology 61
9.3.1 Coverage 61
9.3.2 Secondary Research 62
9.3.3 Forecasting 62
9.3.4 Primary Research 64
9.3.5 Expert Panel Validation 65
9.4 Contact Us 65
9.5 Disclaimer 65
9.6 Bibliography 65

List of Table


Table 1: Anal Cancer Therapeutics - Incidence Rate 6
Table 2: Definitions of TNM 13
Table 3: TNM Classification and Stages of Anal Cancer 13
Table 4: Description of Prophylactic Anal Cancer Vaccine 17
Table 5: Anal Cancer Therapeutics Market, Seven Major Markets, Revenue ($m), 2006-2011 20
Table 6: Anal Cancer Therapeutics Market, Major Markets, Forecast ($m), 2011-2019 22
Table 7: Anal Cancer Therapeutics Market, The US, Revenue ($m), 2006-2011 24
Table 8: Anal Cancer Therapeutics Market, The US, Forecast ($m), 2011-2019 25
Table 9: Anal Cancer Therapeutics Market, The UK, Revenue ($m), 2006-2011 26
Table 10: Anal Cancer Therapeutics Market, The UK, Forecast ($m), 2011-2019 27
Table 11: Anal Cancer Therapeutics Market, France, Revenue ($m), 2006-2011 28
Table 12: Anal Cancer Therapeutics Market, France, Forecast ($m), 2011-2019 29
Table 13: Anal Cancer Therapeutics Market, Germany, Revenue ($m), 2006-2011 30
Table 14: Anal Cancer Therapeutics Market, Germany, Forecast ($m), 2011-2019 31
Table 15: Anal Cancer Therapeutics Market, Italy, Revenue ($m), 2006-2011 32
Table 16: Anal Cancer Therapeutics Market, Italy, Forecast ($m), 2011-2019 33
Table 17: Anal Cancer Therapeutics Market, Spain, Revenue ($m), 2006-2011 34
Table 18: Anal Cancer Therapeutics Market, Spain, Forecast ($m), 2011-2019 35
Table 19: Anal Cancer Therapeutics Market, Japan, Revenue ($m), 2006-2011 36
Table 20: Anal Cancer Therapeutics Market, Japan, Forecast ($m), 2011-2019 37
Table 21: Gardasil Approvals and Fillings 44
Table 22: Anal Cancer Therapeutics - Phase II Pipeline, 2011 47
Table 23: Anal Cancer Therapeutics - Phase I Pipeline, 2011 47
Table 24: Anal Cancer Therapeutics - Preclinical Pipeline, 2011 48
Table 25: Anal Cancer - Clinical Trials by Country, 2011 52
Table 26: Anal Cancer - Clinical Trials by Phase, 2011 53
Table 27: Anal Cancer - Clinical Trials by Status, 2011 54
Table 28: Anal Cancer - Overall Sponsors, 2011 55
Table 29: Anal Cancer - Prominent Sponsors, 2011 56

List of Chart


Figure 1: Human Papillomavirus Infection and Replication in Anogenital Epithelial Cells 7
Figure 2: Anal Cytology Screening for Anal Squamous Intraepithelial Lesions 9
Figure 3: Stages of Anal Cancer 12
Figure 4: Anal Cancer Surgery with Colostomy, 2011 14
Figure 5: Chemotherapy Regimens for Anal Cancer 15
Figure 6: Anal Cancer Treatment by Stage of the Disease, 2011 18
Figure 7: Anal Cancer Treatment Protocols - Chemo-radiation Therapy or Chemotherapy by Stage, 2011 18
Figure 8: Anal Cancer Therapeutics Market, Seven Major Markets, Revenue ($m), 2006-2011 20
Figure 9: Anal Cancer Therapeutics, Market Share ($m), 2011 21
Figure 10: Anal Cancer Therapeutics Market, Major Markets, Forecast ($m), 2011-2019 22
Figure 11: Anal Cancer, Seven Major Markets, Market Share ($m), 2019 23
Figure 12: Anal Cancer Therapeutics Market, The US, Revenue ($m), 2006-2011 24
Figure 13: Anal Cancer Therapeutics Market, The US, Forecast ($m), 2011-2019 25
Figure 14: Anal Cancer Therapeutics Market, The UK, Revenue ($m), 2006-2011 26
Figure 15: Anal Cancer Therapeutics Market, The UK, Forecast ($m), 2011-2019 27
Figure 16: Anal Cancer Therapeutics Market, France, Revenue ($m), 2006-2011 28
Figure 17: Anal Cancer Therapeutics Market, France, Forecast ($m), 2011-2019 29
Figure 18: Anal Cancer Therapeutics Market, Germany, Revenue ($m), 2006-2011 30
Figure 19: Anal Cancer Therapeutics Market, Germany, Forecast ($m), 2011-2019 31
Figure 20: Anal Cancer Therapeutics Market, Italy, Revenue ($m), 2006-2011 32
Figure 21: Anal Cancer Therapeutics Market, Italy, Forecast ($m), 2011-2019 33
Figure 22: Anal Cancer Therapeutics Market, Spain, Revenue ($m), 2006-2011 34
Figure 23: Anal Cancer Therapeutics Market, Spain, Forecast ($m), 2011-2019 35
Figure 24: Anal Cancer Therapeutics Market, Japan, Revenue ($m), 2006-2011 36
Figure 25: Anal Cancer Therapeutics Market, Japan, Forecast ($m), 2011-2019 37
Figure 26: Anal Cancer Therapeutics Market, Drivers and Barriers, 2011 39
Figure 27: Anal Cancer Therapeutics Market, Drivers and Barriers and Its Influence, 2011 39
Figure 28: Opportunity and Unmet Need for Anal Cancer Therapeutics Market, 2011 41
Figure 29: Anal Cancer Therapeutics Market - Strategic Competitor Assessment, 2011 43
Figure 30: Anal Cancer Therapeutics - Pipeline by Phase of Development, (%), 2011 46
Figure 31: Anal Cancer Therapeutics - Pipeline by Phase of Development, 2011 47
Figure 32: Anal Cancer Therapeutics- Clinical Pipeline by Mechanism Of Action, 2011 49
Figure 33: Anal Cancer Therapeutics- Technology Trends Analytics Framework, 2011 50
Figure 34: Anal Cancer - Clinical Trials by Country, 2011 52
Figure 35: Anal Cancer - Clinical Trials by Phase, 2011 53
Figure 36: Anal Cancer - Clinical Trials by Status, 2011 54
Figure 37: Anal Cancer - Overall Sponsors, 2011 55
Figure 38: Anal Cancer - Prominent Sponsors, 2011 56
Figure 39: Implications for Future Market Competition in Anal Cancer Therapeutics Market, 2011 57
Figure 40: Anal Cancer Therapeutics - Pipeline by Company, 2011 58
Figure 41: GlobalData Market Forecasting Model 64

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *